CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
Oxytocin +1 moredrug
Likely dose
Oxytocin 24 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01856530
NCT01856530Phase 2Completed

Effect of Oxytocin on Pro-Social Behavior in Social Anxiety Disorder

Stefan G. Hofmann·interventional·Posted May 17, 2013·Updated Feb 13, 2018

In Brief

A Phase 2 clinical trial evaluating Oxytocin and Placebo for Social Anxiety Disorder. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The purpose of this study is to learn more about how the hormone, oxytocin, impacts social behavior in terms of cooperation with others, attention processing, and reward processing, among patients with social anxiety disorder. Based on available research, the investigators predict that in patients with social anxiety disorder, oxytocin will improve social cooperation during an online ball-tossing game called Cyberball, reduce attention toward socially threatening cues during a dot-probe task, and lead to greater willingness to work for monetary rewards for others rather than themselves during an effort expenditure task.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 17, 2013
Enrollment StartJul 1, 2012
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 13.1 years ago

Interventions

Oxytocindrug

Liquid metered-dose nasal spray, 24 IU, administered once

Placebodrug

Matched placebo nasal spray